Repligen (NASDAQ:RGEN) had its price objective raised by JPMorgan Chase & Co. to $60.00 in a research report released on Monday, The Fly reports. The brokerage currently has an overweight rating on the biotechnology company’s stock.

Other analysts have also issued research reports about the company. Stephens raised their target price on Repligen from $50.00 to $55.00 and gave the company an average rating in a report on Tuesday, July 10th. BidaskClub lowered Repligen from a strong-buy rating to a buy rating in a report on Tuesday, July 31st. Citigroup raised their target price on Repligen from $45.00 to $56.00 and gave the company a buy rating in a report on Friday, July 20th. ValuEngine raised Repligen from a hold rating to a buy rating in a report on Thursday, June 28th. Finally, Zacks Investment Research lowered Repligen from a hold rating to a sell rating in a report on Tuesday, August 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $49.43.

Shares of NASDAQ RGEN opened at $55.07 on Monday. The stock has a market cap of $2.42 billion, a PE ratio of 79.81, a P/E/G ratio of 4.45 and a beta of 0.72. Repligen has a 52 week low of $29.56 and a 52 week high of $58.99.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported $0.16 EPS for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.02). The company had revenue of $47.73 million for the quarter, compared to analyst estimates of $45.84 million. Repligen had a net margin of 13.49% and a return on equity of 5.05%. The business’s revenue was up 47.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.20 EPS. analysts expect that Repligen will post 0.71 earnings per share for the current year.

In other Repligen news, CEO Anthony Hunt sold 27,566 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $57.71, for a total value of $1,590,833.86. Following the completion of the sale, the chief executive officer now owns 255,017 shares in the company, valued at approximately $14,717,031.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Nicolas Barthelemy sold 6,580 shares of the firm’s stock in a transaction that occurred on Wednesday, August 29th. The stock was sold at an average price of $54.44, for a total value of $358,215.20. Following the completion of the sale, the director now owns 8,774 shares of the company’s stock, valued at approximately $477,656.56. The disclosure for this sale can be found here. Insiders sold a total of 88,884 shares of company stock worth $4,693,683 in the last ninety days. Insiders own 1.40% of the company’s stock.

Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its position in shares of Repligen by 9.1% in the 2nd quarter. BlackRock Inc. now owns 5,851,161 shares of the biotechnology company’s stock worth $275,239,000 after acquiring an additional 485,777 shares during the period. OppenheimerFunds Inc. lifted its position in shares of Repligen by 7.4% during the 2nd quarter. OppenheimerFunds Inc. now owns 2,135,929 shares of the biotechnology company’s stock worth $100,473,000 after buying an additional 146,290 shares during the period. Conestoga Capital Advisors LLC lifted its position in shares of Repligen by 6.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,711,132 shares of the biotechnology company’s stock worth $80,492,000 after buying an additional 107,095 shares during the period. Macquarie Group Ltd. lifted its position in shares of Repligen by 12.3% during the 2nd quarter. Macquarie Group Ltd. now owns 1,107,691 shares of the biotechnology company’s stock worth $52,106,000 after buying an additional 121,157 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Repligen by 0.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,016,820 shares of the biotechnology company’s stock worth $47,831,000 after buying an additional 3,489 shares during the period. Institutional investors own 92.50% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: Day Trading

The Fly

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.